Light in sight: A step towards a potential therapy for acquired blindness

7 mayo 2015

A promising new therapeutic approach for hereditary blindness based on a technology termed ‘optogenetics’ is to introduce light-sensing proteins into these surviving retinal cells, turning them into ‘replacement photoreceptors’ and thereby restoring vision. However, several factors limit the feasibility of a clinical optogenetic therapy using traditional light-sensitive proteins, as they require unnaturally high and potentially harmful light intensities and employ a foreign signaling mechanism within the target retinal cells.